Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

TEVA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025

Richard Francis is the CEO of Teva Pharmaceutical Industries and was paid $19.2M in FY2025 (Dec), up 24%.

PayNo stock prices for these years
CEO pay is from each Teva Pharmaceutical Industries proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Richard FrancisFY2025
  2. 2Evan LippmanFY2025
  3. 3Eli KalifFY2025
  4. 4Dr. Eric HughesFY2025
  5. 5Christine FoxFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Teva Pharmaceutical Industries paid its 5 named executives $45.5M in total in FY2025 (Dec). CEO Richard Francis was paid $19.2M of that.

Name
Richard FrancisPresident and Chief Executive Officer
Evan LippmanExecutive Vice President, Business DevelopmentNot disclosedNot disclosed
Eli KalifExecutive Vice President, Chief Financial Officer
Dr. Eric HughesExecutive Vice President, Global R&D and Chief Medical OfficerNot disclosed
Christine FoxExecutive Vice President, US CommercialNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Teva Pharmaceutical Industries. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Tal ZaksDirector · 4 yr on the boardIndependentFinance and Investment, Science and Technology—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Left the market
    Teva Pharmaceutical Industries left the market on Sep 14, 2026 (Form 25-NSE).
    25
  2. Pay
    Teva Pharmaceutical Industries CEO pay rose 24% to $19.2M in FY2025 (Dec).
    DEF 14A
  3. Pay
    Teva Pharmaceutical Industries CEO pay fell 40% to $15.5M in FY2024 (Dec).
    DEF 14A
  4. Pay
    Teva Pharmaceutical Industries CFO pay rose 13% to $7.0M in FY2025 (Dec).
    DEF 14A
  5. Pay
    Teva Pharmaceutical Industries Division head pay rose 13% to $5.9M in FY2025 (Dec).
    DEF 14A
  6. Pay
    Teva Pharmaceutical Industries CEO pay fell 40% to $15.5M in FY2024 (Dec).
    DEF 14A
  7. Pay
    Teva Pharmaceutical Industries CFO pay rose 25% to $6.2M in FY2024 (Dec).
    DEF 14A
  8. Pay
    Teva Pharmaceutical Industries CFO pay rose 13% to $4.0M in FY2022 (Dec).
    DEF 14A
  9. Pay
    Teva Pharmaceutical Industries CFO pay rose 23% to $4.9M in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AMar 31, 2026FY2025
Annual report10-KFeb 3, 2026FY2025
Proxy statementDEF 14AApr 9, 2025FY2024
Annual report10-KFeb 5, 2025FY2024
Proxy statementDEF 14AApr 16, 2024FY2023
Annual report10-KFeb 12, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data